SINTX Technologies Faces Cash Crunch Despite FDA Foot Device Win
SINTX Technologies details 2025 operations and risks
2026.03.20Updated 15d ago
SINTX Technologies’ 2025 annual report highlights $10.4M net loss, $4.1M cash, new SiNAPTIC foot and ankle FDA clearance, and an extensive silicon nitride patent portfolio and risk factors.
AI SummaryPowered by AI
SINTX Technologies reported a $10.4M net loss in 2025 with only $4.1M in cash reserves. The medical device company secured FDA clearance for its new SiNAPTIC foot and ankle implant. The firm's extensive silicon nitride patent portfolio provides competitive advantage amid significant operational risks.
Original Article
Read full article on sourcesintx technologiessinaptic implantfda clearancesilicon nitridemedical devicesorthopedicpatent portfoliocash reservessintxtechnologies
Explore More
Related News
Silverline Technologies Shifts Focus Amid User Surge | Technology
Devdiscourse · 2026.04.03
Saronic Technologies: Redefining maritime superiority
Bessemer Venture Partners · 2026.04.03
MoldTek Technologies Ltd is Rated Sell
2026.04.03
Merging Technologies releases Pyramix 16
Mixdown Magazine · 2026.04.02
JAPAN-CLIMATE-ENERGY-TECHNOLOGY-ENVIRONMENT • Channels Television
Channels Television · 2026.04.05
Mustard Debate: Tradition vs Technology
Devdiscourse · 2026.04.05